Androgen deprivation therapy and Gleason grade: unravelling implications on survival

The efficacy of concurrent androgen deprivation therapy (ADT) with radiation therapy among patients with high-risk prostate cancer is well documented. A meta-analysis by Kishan et al. (1) compared the effect of ADT duration on survival in patients with Gleason grade group (GGG) 4 and GGG 5 prostate cancer receiving radiation therapy by performing an individual patient-level network meta-analysis with data from six randomized controlled trials. Due to the significant adverse effects of ADT, efforts have been made to assess the efficacy of shorter ADT durations. The present study investigated if the effect of ADT duration on survival differed between patients with GGG 4 and GGG 5 disease.

The study compared overall survival (OS), cancer specific survival (CSS), and distant metastasis free survival (DMFS) among GGG 4 (n=593) and GGG 5 (n=399) patients who received radiation therapy alone, short-term ADT, long-term ADT, and lifelong ADT.

Both short-term ADT (HR 0.43; 95% CI, 0.26–0.70; P=0.03) and long-term ADT (HR 0.59; 95% CI, 0.38–0.93; P=0.03) improved OS as compared to radiation therapy alone in GGG 4 patients. However, lifelong ADT showed no difference in OS compared to radiation therapy alone in GGG 4 patients (HR 0.84; 95% CI, 0.54–1.30; P=0.44). The trend in these effects (with a diminishing benefit to ADT with increasing duration), suggests that while the concurrent administration of ADT with radiotherapy provides significant benefit, the harms of ADT may outweigh its advantages while administered for long durations in this patient population.

In contrast, among GGG 5 patients, there was an improvement in OS for patients that received lifelong ADT (HR 0.48; 95% CI, 0.31–0.76; P=0.04) but not among those receiving long-term (HR 0.80; 95% CI, 0.45–1.44; P=0.45) or short-term ADT (HR 1.13; 95% CI, 0.69–1.87; P=0.64). This suggests that, even among patients with apparently localized disease, patients with GGG5 disease benefit from treatment approaches more in keeping with men with disseminated disease.

In patients who received short-term ADT and in all patients studied, GGG 5 patients exhibited worse OS compared to GGG 4 patients (HR 1.40; 95% CI, 1.05–1.88; P=0.05 and HR 1.25; 95% CI, 1.07–1.47; P=0.04, respectively). Among patients who received long-term or lifelong ADT, there was no difference in OS between GGG 5 and GGG 4 patients (HR 1.21; 95% CI, 0.89–1.65; P=0.23 and HR 0.85; 95% CI, 0.53–1.37; P=0.52, respectively) (1).

Management of prostate cancer has changed significantly since the studies included in this meta-analysis were published. The NCCN guidelines for treatment of prostate cancer recommend radiation dosages of up to 75.2–81.0 Gy for treatment of high-risk disease (2). Among the included studies, only one utilized radiation dosages in this range with a subset of patients in EORTC 22991 trial receiving dosages up to 78 Gy (3). The other studies included did not exceed dosages of 72 Gy, with most using a maximum of 70 Gy (4-8). Giving lower radiation dosages than suggested by current guidelines may affect the relationship between the administration of ADT and OS due to less effective local radiation therapy. With greater efficacy of radiation therapy protocols today, it is possible that patients with GGG 5 disease would have greater survival benefit with short and long-term ADT. Alternatively, more effective local therapy may obviate the benefit of systemic ADT.

In addition to changes in radiation treatment, there have been significant advances in imaging technologies that have improved the ability to diagnose and stage advanced prostate cancer. ⁶⁸Ga-PSMA positron emission tomography/computed tomography (PET/CT) offers significantly increased sensitivity in detecting nodal and distant metastases compared to other imaging modalities (9). Additionally, ⁶⁸Ga-PSMA PET/CT has improved the ability to detect recurrent prostate cancer, especially at lower PSA levels (10). As the authors note, the less sensitive staging modalities available at the time of the included trials introduces the possibility of unknown metastatic burden among the study patients that may have impacted the greater benefit of lifelong ADT (vs. shorter regimens) in GGG 5 patients. Today, the ability to more accurately stage high-risk prostate cancer using more sensitive modalities provides better patient selection and validity to results of clinical trials.

When evaluating the application of these results to clinical practice, it is important to consider the adverse effects of ADT and their impact on patient quality of life (11,12). Known toxicities of ADT include fatigue, osteoporosis, decreased sexual function, hot flashes, depression, alterations in blood lipid levels, cognitive dysfunction, and metabolic effects (13,14). Additionally, longer duration of ADT has been associated with greater risk of these adverse effects in a dose-dependent fashion (13). Awareness of ADT side effects is especially important when weighing the increased survival associated with lifelong ADT in patients with GGG 5 disease, as these patients should be counseled on these adverse effects prior to starting treatment. Furthermore, intermittent ADT, which was not mainstream during accrual for these trials, as noninferior to continuous ADT has significant implications on the application of these results. Intermittent ADT offers improved quality of life and similar overall survival to continuous ADT (15). The use of intermittent ADT in GGG 5 patients may improve survival with less negative impact on quality of life and minimize the deleterious, cumulative effects of prolonged ADT.

The data reported by Kishan et al. suggesting differential survival among GGG 4 and GGG 5 for patients receiving short-term, long-term, and lifelong ADT has treatment implications for high-risk patients. Despite limitations, these data suggest that these high-risk patients should not be considered equivalent and that nuanced prescribing of ADT may improve outcomes for patients with high grade prostate cancer undergoing radiotherapy.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned and reviewed by the Section Editor Hong-chao He (Department of Urology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China).

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.04.12). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Kishan AU, Wang X, Seiferheld W, et al. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. JAMA Oncol 2019;5:91-6. [Crossref] [PubMed]
2. Network NCC. Prostate Cancer (Version 1.2019). 2019. Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 4/6/2019.
3. Bolla M, Maingon P, Carrie C, et al. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. J Clin Oncol 2016;34:1748-56. [Crossref] [PubMed]
4. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-27. [Crossref] [PubMed]
5. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300. [Crossref] [PubMed]
6. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-504. [Crossref] [PubMed]
7. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52. [Crossref] [PubMed]
8. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90. [Crossref] [PubMed]
9. Schmidt-Hegemann NS, Fendler WP, Buchner A, et al. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Radiat Oncol 2017;12:176. [Crossref] [PubMed]
10. von Eyben FE, Picchio M, von Eyben R, et al. (68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus 2018;4:686-93. [Crossref] [PubMed]
11. Wallis CJ, Mahar AL, Satkunasivam R, et al. Cardiovascular and Skeletal-Related Events Following Localised Prostate Cancer Treatment: Role of Surgery, Radiotherapy and Androgen-Deprivation. Urology 2016;97:145-52. [Crossref] [PubMed]
12. Wallis CJD, Satkunasivam R, Herschorn S, et al. Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer. Urol Oncol 2018;36:241.e1-6. [Crossref] [PubMed]
13. Dinh KT, Reznor G, Muralidhar V, et al. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol 2016;34:1905-12. [Crossref] [PubMed]
14. Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67:825-36. [Crossref] [PubMed]
15. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895-903. [Crossref] [PubMed]